Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. - Wikidata - awgldk - TriplyDB

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q37592115

about

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib Adopting ALK and LTK.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.Inhibiting TRK Proteins in Clinical Cancer Therapy.

P2860

Q33804619-1F5D7E60-0529-4ED0-8E3E-B1ED0B0E5D7F Q36435102-93295378-5AF9-45D7-BA90-22CE6A92ADDA Q37666880-E9ECB2C1-ACE2-4A63-8CE0-95AA0DBD9161 Q38443447-F7D516D5-801A-45BF-A6BB-F951A9ECE230 Q39220897-66A8DD83-F4A1-4DB1-8E7E-B73839CF424E Q46603813-1E413629-7719-4CC4-A187-1CA9264D1544 Q54117764-59450C0F-1051-4867-9D3C-E91454FF7D5F

P2860

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q37592115

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@en

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@nl

type

label

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@en

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@nl

prefLabel

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@en

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@nl

P1433

Q37592115-28B054A6-7C1C-44B2-B7E9-BE71D068F9F6

P1476

Q37592115-3CC6B861-C24C-4E1C-89B2-7F9E0E787E98

P2093

Q37592115-22B722DF-F885-4086-B24C-F267B697A778

P2860

Q37592115-037A88B9-CD72-4936-B43A-86645FB9A26F

Q37592115-0749EC01-5488-4A5C-9458-F5E3F515E93C

Q37592115-0751828B-5565-4349-805B-1EACB6CAD9B9

Q37592115-12BE90D4-8005-4F29-9BAC-6DF7B4B3C1A8

Q37592115-1340E7DF-7D25-4003-B665-503B654829F9

Q37592115-230FAC4C-E399-40F3-B7D0-C7A2C2C2113F

Q37592115-3A55E023-A045-4B0A-B459-771BF241725D

Q37592115-3BD66C16-C86C-4E93-B4CF-B9DE1B4A3946

Q37592115-450AE797-BDCE-418A-AD37-960CF1C19D70

Q37592115-45772D37-D33B-46DE-857F-04AC0F6B4AE2

P304

Q37592115-FFF9050D-197B-4D11-B436-7DA21E7B4EFB

P31

Q37592115-CA944420-5E09-48A5-8512-B6B81159BD2F

P356

Q37592115-3385CE6A-7FDE-49D9-9735-9877BF9A7891

P433

Q37592115-7276754F-936B-4BDE-892F-35BAB3ACB61A

P478

Q37592115-82A90A46-9079-40FC-95CD-FB26E7C6EAA6

P50

Q37592115-596DCAC3-C07A-4AC6-8536-14E05C64C8BB

P577

Q37592115-DA16AB96-AC72-428B-8ABE-B3018F820419

P698

Q37592115-D01A623A-8005-4776-86B7-0C459E52AA78

P932

Q37592115-83FB1B74-83EA-4ED6-9CBF-F1A64C489905

P356

PPO.0000000000000142

P1433

The Cancer Journal

P1476

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

@en

P2093

Wade T Iams

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

P304

378-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PPO.0000000000000142

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Christine M. Lovly

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26389762

http://www.w3.org/2001/XMLSchema#string

P932

5242382

http://www.w3.org/2001/XMLSchema#string